Davis Polk advised the representatives of the several underwriters in connection with Iterum Therapeutics plc’s initial public offering of 6,150,000 ordinary shares, at $13.00 per share,…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
